Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Enzalutamide
Indication/Tumor Type prostate cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable Enzalutamide FDA approved Actionable In a Phase III trial (AFFIRM) that supported FDA approval, treatment with Xtandi (enzalutamide) resulted in improved median overall survival compared to placebo (18.4 vs 13.6 months HR=0.63, p<0.001) in patients with metastatic castration-resistant prostate cancer (PMID: 22894553; NCT00974311). detail... 22894553
Unknown unknown prostate cancer not applicable Enzalutamide FDA approved Actionable In a Phase III trial (PROSPER) that supported FDA approval, Xtandi (enzalutamide) significantly improved median metastasis-free survival (36.6 vs 14.7 months, HR=0.29, p<0.0001) compared to placebo in patients with non-metastatic castration-resistant prostate cancer (Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 3-3; NCT020032924). detail... detail...
Unknown unknown prostate cancer not applicable Enzalutamide FDA approved Actionable Ina Phase III trial (ARCHES) that supported FDA approval, Xtandi (enzalutamide) treatment with androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death compared to ADT plus placebo (HR=0.39, P < .001; median not reached vs 19.0 months) in patients with metastatic hormone-sensitive prostate cancer (PMID: 31329516; NCT02677896). detail... 31329516
PubMed Id Reference Title Details
(22894553) Increased survival with enzalutamide in prostate cancer after chemotherapy. Full reference...
PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). Full reference...
Xtandi (enzalutamide) FDA Drug Label Full reference...
Xtandi (enzalutamide) FDA Drug Label Full reference...
Xtandi (enzalutamide) FDA Drug Label Full reference...
(31329516) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Full reference...